Bitcoin is currently trading around $84,000, down 2% in the last 24 hours, with prediction markets assigning only a 40% chance of reaching $100,000 soon. Analyst Ted Pillows suggests that Bitcoin is unlikely to make a decisive upward move until the end of the year, expecting a price correction and sideways trading first. While some analysts are optimistic about a strong finish to 2026 leading to a major bull market in early 2027, current price action in October has been slow and somewhat bearish, casting doubt on the "Uptober" bullish trend. The next three weeks will be critical for traders as the market decides its direction.
Bitcoin price outlook is discussed with prediction markets giving a 40% chance of reaching $100,000. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 09, 2026 00:32 WIB: out of 50 major cryptocurrencies, 4 rose and 45 fell today. Notable movers include SAND at Rp1.185 with a -19.38% change, MANA at Rp1.625 with -12.87%, and AVAX at Rp176.196 with -12.31%.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...
Equifax has introduced Mortgage Score Select, a new tool allowing mortgage lenders and brokers to choose which credit score to include on a mortgage credit file or to pull the file without a score. This innovation offers cost savings by enabling a se...
Nearly 2,000 mortgage lenders are using Equifax's VantageScore 4.0 credit scoring model, which incorporates alternative data like rental and utility payments, to improve borrower evaluation and expand credit access. Equifax has extended the $1 pricin...
Ashish Kumar, former AI lead for Tesla's humanoid robot Optimus, has founded Intelligent Machines, a startup focused on building task-specific industrial robots rather than humanoid ones. The company uses reinforcement learning to train robots for sp...
argenx SE (ARGX) shares fell over 10% on October 8, 2026, after the company stopped its Phase 3 UNITY trial of subcutaneous Vyvgart for Sjögren's disease due to futility. An independent committee found the study unlikely to meet its primary endpoint,...
